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ABSTRACT
Background The EQ-5D, a generic health status
questionnaire that is widely used in health economic
evaluation, was recently expanded to the EQ-5D-5L to
address criticisms of unresponsiveness and ceiling effect.
Aims To describe the validity, responsiveness and
minimum important difference of the EQ-5D-5L in COPD.
Methods Study 1: The validity of the EQ-5D-5L utility
index and visual analogue scale (EQ-VAS) was compared
with four established disease-speciﬁc health status
questionnaires and other measures of disease severity
in 616 stable outpatients with COPD. Study 2: The EQ-
5D-5L utility index and EQ-VAS were measured in 324
patients with COPD before and after 8 weeks of
pulmonary rehabilitation. Distribution and anchor-based
approaches were used to estimate the minimum
important difference.
Results There were moderate-to-strong correlations
between utility index and EQ-VAS with disease-speciﬁc
questionnaires (Pearson’s r=0.47–0.72). A ceiling effect
was seen in 7% and 2.6% of utility index and EQ-VAS.
Utility index decreased (worsening health status) with
indices of worsening disease severity. With rehabilitation,
mean (95% CI) changes in utility index and EQ-VAS
were 0.065 (0.047 to 0.083) and 8.6 (6.5 to 10.7),
respectively, with standardised response means of 0.39
and 0.44. The mean (range) anchor estimates of the
minimum important difference for utility index and EQ-
VAS were 0.051 (0.037 to 0.063) and 6.9 (6.5 to 8.0),
respectively.
Conclusions The EQ-5D-5L is a valid and responsive
measure of health status in COPD and may provide
useful additional cost-effectiveness data in clinical trials.
INTRODUCTION
The EQ-5D is a simple, generic health-related
quality of life (HRQoL) instrument that is self-
administered and is widely used as a patient-
reported outcome measure. It comprises ﬁve health
dimensions (mobility, self-care, usual activities,
pain/discomfort and anxiety/depression): the most
commonly used version of the questionnaire, the
EQ-5D-3L, has three levels of severity for each
dimension.1 The EQ-5D is widely used in health
economic evaluation—a utility index (UI) can be
calculated by applying ‘social tariffs’, which are
used to estimate health beneﬁts in terms of
quality-adjusted life-years (QALYs). It is one of only
a few measures recommended for use in
cost-effectiveness analyses by the Washington Panel
on Cost Effectiveness in Health & Medicine, while
the United Kingdom National Institute for Health
and Care Excellence has recommended the EQ-5D
to be the preferred HRQoL instrument to generate
QALYs.2
Other advantages for using generic instruments
include the comparison of HRQoL across different
diseases, and the potential for capturing aspects of
HRQoL that may not be addressed by disease-
speciﬁc questionnaires. For example, in patients
with COPD, the EQ-5D may better reﬂect side
effects of extrapulmonary manifestations such as
cardiac comorbidity3 or sarcopenia.4
The EQ-5D-3L is simple and quick to use with
high patient completion rates in general and
COPD-speciﬁc populations,5 6 and has been
reported in some trials of patients with COPD.7–9
However, investigators have questioned the ability
of the EQ-5D-3L to differentiate small changes in
health status, and therefore, it may be less respon-
sive than disease-speciﬁc HRQoL questionnaires in
COPD.6 10 Furthermore, the EQ-5D is well recog-
nised to have a signiﬁcant ceiling effect (ie, scores
recording perfect health) in both general and
disease-speciﬁc populations,6 11 leaving less room
for improvement in response to an intervention.
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Key messages
What is the key question?
▸ What is the validity, responsiveness and
minimum important difference of the EQ-5D-5L,
a generic health status questionnaire that is
widely used in health economic evaluation, in
patients with COPD?
What is the bottom line?
▸ This is the ﬁrst study to demonstrate that the
EQ-5D-5L utility index and visual analogue
score are valid and responsive in stable COPD
and provides estimates of the minimum
clinically important difference.
Why read on?
▸ This data will help in the design of clinical
intervention trials, particularly with regard to
assessment of cost-effectiveness.
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To address these issues, the EQ-5D-5L was developed in
201112 with the levels of severity for each dimension increased
to a choice of ﬁve, thus allowing the description of 3125 differ-
ent health states, in comparison to the 243 health states possible
in the EQ-5D-3L. However, studies examining the psychometric
properties of the EQ-5D-5L are limited. Furthermore, previous
studies have only estimated the UI of the EQ-5D-5L as a ‘cross-
walk’ value by mapping to the EQ-5D-3L.13 Recently, the
EQ-5D-5L value set for England, derived from 1000 individuals
selected at random from the adult general population of
England, was published, thus allowing the UI to be directly cal-
culated.14 In addition to the UI, the EQ-5D-5L (like the 3L)
includes a visual analogue scale (EQ-VAS).
The aim of the current study was to assess the validity of the
EQ-5D-5L UI and EQ-VAS in a COPD-speciﬁc outpatient popu-
lation by comparing with well-established disease-speciﬁc
HRQoL questionnaires and other indices of disease severity.
The responsiveness of the UI and EQ-VAS was also tested in a
separate COPD cohort undergoing pulmonary rehabilitation.
Finally, the minimum important difference (MID)—the smallest
change in score that patients perceive as beneﬁcial or detrimen-
tal—of the UI and EQ-VAS were estimated using a range of
anchor-based and distribution-based methods.
We hypothesised that (1) the EQ-5D-5L would correlate sig-
niﬁcantly with COPD-speciﬁc HRQoL questionnaires and be
able to distinguish different levels of disease severity; (2) the
EQ-5D-5L would improve with pulmonary rehabilitation; and
(3) that change in EQ-5D-5L would correlate signiﬁcantly with
change in COPD-speciﬁc HRQoL questionnaires with pulmon-
ary rehabilitation.
METHODS
Participants
All participants had a diagnosis of COPD according to the
global initiative for chronic obstructive lung disease (GOLD) cri-
teria.15 This study was a secondary analysis of data from two
cohorts of patients with COPD recruited in order to determine
whether the presence of sarcopenia and frailty impacts upon
prognosis in COPD.4
Study 1: validity of the EQ-5D-5L in outpatients with COPD
This was a cross-sectional cohort study that took place between
April 2012 and October 2014. The EQ-5D-5L,12 COPD assess-
ment test (CAT),16 St George’s respiratory questionnaire
(SGRQ),17 the self-report chronic respiratory questionnaire
(CRQ)18 and the clinical COPD questionnaire (CCQ)19 were
measured in 616 outpatients attending respiratory clinics at
Hareﬁeld Hospital. Spirometry20 and the Medical Research
Council Dyspnoea Scale (MRC)21 were also recorded. The age
dyspnoea obstruction (ADO) index, a validated composite prog-
nostic score in COPD22 and surrogate marker of disease severity,
was calculated.22
Study 2: response of the EQ-5D-5L to pulmonary
rehabilitation
Between August 2013 and October 2014, 400 participants were
recruited from pulmonary rehabilitation clinics at Hareﬁeld
Hospital to this prospective cohort study. Additional inclusion
criteria were an ability to walk 5 m without assistance and no
contraindication to aerobic exercise.
The EQ-5D-5L, CAT, SGRQ and CRQ were prospectively
measured at baseline, and following an 8-week outpatient PR
programme, comprising twice-weekly supervised exercise and
education sessions.4 In addition to questionnaires, the
incremental shuttle walk, the ﬁve-repetition sit-to-stand and the
4 m gait speed were measured to assess change in physical per-
formance.23–25 Participants, blinded to the results of their post-
pulmonary rehabilitation assessments, rated their overall change
in health status following rehabilitation using an adapted ﬁve-
point global rating of change questionnaire26 ‘1: much better’;
‘2: a little better’; ‘3: no change’; ‘4: a little worse’ and ‘5:
much worse’.
The EQ-5D-5L and disease-speciﬁc HRQoL questionnaires
The scoring of the EQ-5D-5L (UI and EQ-VAS) and the disease-
speciﬁc questionnaires (CAT, SGRQ, CCQ and CRQ) are
detailed in the online supplementary material. To summarise,
the EQ-5D-5L comprises two components: the UI and the
EQ-VAS. The UI is calculated from patient scoring of ﬁve
dimensions (mobility, self-care, usual activities, pain/discomfort,
anxiety/depression). For each dimension, participants are asked
to mark between 1: ‘no problems’ to 5: ‘unable to/extreme pro-
blems’. The responses are combined to produce a ﬁve-digit
number describing the participant’s health status (ranging from
11111 to 55555). This is converted to a UI based on the
EQ-5D-5L value set for England14 (see online supplementary
ﬁgure S1). The UI ranges from −0.208 (worst possible health)
to 1.000 (best possible health). For the EQ-VAS, participants are
asked to record their self-rated health on a vertical VAS with the
end points ‘The worst health you can imagine’ and ‘The best
health you can imagine’ at the bottom (‘0’) and top of the scale
(‘100’), respectively. Hence, an improvement in HRQoL is asso-
ciated with an increase in UI and EQ-VAS.
The CAT was reported as a single score (0–40), the SGRQ
was reported as individual domain (symptoms, activity, impact)
and total scores (0–100),17 and the CCQ was reported as indi-
vidual domain (symptoms, function and mental) and total
scores (0–6).19 For these three questionnaires, a higher score
equates to worse HRQoL. The CRQ was expressed as individual
domain (dyspnoea (5–35), fatigue (4–28), emotion (7–49),
mastery (4–28)) and total summed scores (20–140), with higher
scores equating to better HRQoL.18
Data analysis
Data analyses and graphs were produced using SPSS V.21 (IBM,
USA) and Prism 5 (GraphPad, USA). Baseline characteristics were
presented as mean (SD). Pearson’s r correlation coefﬁcients
(where the null hypothesis=no correlation) were used to report
associations between EQ-5D-5L and other questionnaires. UI
and EQ-VAS were reported in groups stratiﬁed according to
GOLD spirometric stage, MRC dyspnoea scale and the ADO
index to assess the association with disease severity. One-way ana-
lysis of variance (ANOVA) was used for multiple group compari-
sons. As there were few patients in GOLD spirometric stage 1 or
with MRC 1, GOLD spirometric stages 1 and 2, and MRC 1 and
2 were grouped together for the purposes of analysis. Changes in
outcomes before and after PR were compared using paired t
tests. Responsiveness was expressed as standardised response
means (mean change/SD of change).
MID was estimated using distribution-based (half SD) and
anchor-based methods (linear regression and receiver operating
characteristic (ROC) plots).16 We calculated the mean (95% CI)
change in UI and EQ-VAS in those reporting feeling ‘a little
better’ with rehabilitation on the global rating of change ques-
tionnaire. Further details of the linear regression and ROC ana-
lysis are described in the online supplementary material.
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RESULTS
Study 1: validity of the EQ-5D-5L in outpatients with COPD
Complete EQ-5D-5L data were obtained in 616 of 625 patients
approached. The study ﬂow chart is shown in the online
supplementary material. Baseline characteristics of the cohort
are presented in table 1. Figure 1 shows the distribution of
responses to the EQ-5D-5L descriptive system. The mobility
and usual activities dimensions showed the greatest self-reported
impairment with 58% and 53% of the cohort reporting at least
moderate problems, respectively.
Mean (SD) UI was 0.681 (0.236) and ranged from −0.160 to
1.000, with 43 patients (7%) describing perfect health and ﬁve
patients with a negative UI (health state worse than death).
Mean (SD) EQ-VAS was 60.95 (20.62). Sixteen patients (2.6%)
reported an EQ-VAS of 100 (best possible health) and two
patients reported an EQ-VAS of 0 (worst possible health).
Table 1 describes the relationships between UI and EQ-VAS
with baseline characteristics and disease-speciﬁc HRQoL ques-
tionnaires. There were signiﬁcant but weak correlations (r<0.2)
between EQ-5D-5L variables and age, body mass index, FEV1
and smoking pack years. There were moderate-to-strong correla-
tions between EQ-5D-5L variables and disease-speciﬁc HRQoL
questionnaire total scores, with Pearson’s r ranging from 0.47 to
0.72. In general, the correlations between disease-speciﬁc
HRQoL questionnaires were stronger with the UI than with
EQ-VAS (table 1). Figure 2 demonstrates the relationship
between UI and EQ-VAS with CRQ total score.
UI decreased (worsening HRQoL) with increasing GOLD
stage (worsening FEV1) (ANOVA: p=0.004), increasing MRC
(p<0.001) and increasing ADO index (p<0.001). EQ-VAS
decreased (worsening HRQoL) with increasing GOLD stage
(p=0.014), increasing MRC and ADO index (p both <0.001)
(ﬁgure 3). On two group comparison, neither UI nor EQ-VAS
was able to clearly differentiate between GOLD 1/2 from
GOLD 3.
Study 2
Response to pulmonary rehabilitation
Complete pre-EQ-5D-5L and post-EQ-5D-5L data were
recorded in 324 of 400 patients (81% completion rate; see
study ﬂow chart in online supplementary material). As expected,
all measures of physical performance and HRQoL improved
with pulmonary rehabilitation (table 2). With regard to ceiling
effect, 19 (6%) and 36 patients (11%) reported a UI of 1.00
before and after rehabilitation, while 10 (3%) and 14 (4%)
patients reported an EQ-VAS score of 100 before and after
rehabilitation. The distribution of responses to the descriptive
system of the EQ-5D-5L are shown in ﬁgure 4. Standardised
response means were 0.39 and 0.44 for UI and EQ-VAS,
respectively. Standardised response means were 0.51, 0.52 and
0.76 for the CAT, SGRQ total score and CRQ total score,
respectively, and 0.85, 0.73 and 0.62 for shuttle walk, gait
speed and sit-to-stand, respectively.
Estimation of the minimum important difference
Using 0.5 SD, the distribution-based estimates for the MID of
the UI and EQ-VAS were 0.109 and 10.1, respectively. Figure 5
demonstrates the mean (95% CI) changes in UI and EQ-VAS
according to global rating of change questionnaire response. In
total, 173 (53%) patients reported feeling much better, 124
(38%) patients reported feeling a little better, 20 (6%) patients
reported no change and 7 (2%) reported feeling a little worse.
No patient reported feeling ‘much worse’ following pulmonary
rehabilitation. The mean (95% CI) changes in UI and EQ-VAS
in those reporting feeling ‘a little better’ following rehabilitation
Figure 1 Distribution of responses to the descriptive system of the
EQ-5D-5L, from which the utility index is derived.
Table 1 Baseline characteristics and Pearson’s correlation
coefficients with EQ-5D-5L utility index and EQ-VAS (n=616)
Characteristic Mean (SD)
Pearson’s correlation coefficient with
EQ-5D-5L
Utility index EQ-VAS
r p Value r p Value
Age (years) 70.4 (9.3) 0.138 <0.001 0.039 0.330
Male (%) 59.7
Smoking pack years 43.4 (34.8) −0.123 0.003 −0.163 <0.001
BMI (kg/m2) 27.5 (6.8) −0.132 0.001 −0.104 0.010
FEV1 (% predicted) 46.1 (19.6) 0.156 0.002 0.112 0.006
MRC 3.4 (1.0) −0.490 <0.001 −0.376 <0.001
SGRQ symptoms 67.5 (26.4) −0.257 <0.001 −0.283 <0.001
SGRQ activities 69.2 (21.2) −0.603 <0.001 −0.409 <0.001
SGRQ impact 36.1 (19.9) −0.596 <0.001 −0.457 <0.001
SGRQ total 51.1 (18.2) −0.623 <0.001 −0.469 <0.001
CRQ dyspnoea 13.7 (5.4) 0.403 <0.001 0.346 <0.001
CRQ fatigue 13.8 (5.3) 0.572 <0.001 0.500 <0.001
CRQ emotion 30.4 (9.6) 0.593 <0.001 0.468 <0.001
CRQ mastery 17.4 (5.8) 0.578 <0.001 0.426 <0.001
CRQ total 75.2 (21.9) 0.704 <0.001 0.518 <0.001
CAT 20.7 (8.2) −0.528 <0.001 −0.428 <0.001
CCQ symptoms 2.8 (1.3) −0.483 <0.001 −0.406 <0.001
CCQ function 2.8 (1.5) −0.674 <0.001 −0.459 <0.001
CCQ mental 2.9 (1.8) −0.507 <0.001 −0.382 <0.001
CCQ total 2.9 (1.3) −0.626 <0.001 −0.483 <0.001
Utility index 0.68 (0.24) 0.538 <0.001
EQ-VAS 61.0 (20.6) 0.538 <0.001
Data expressed as mean (SD) or Pearson’s r.
BMI, body mass index; CAT, COPD assessment test; CCQ, clinical COPD questionnaire;
CRQ, chronic respiratory questionnaire; MRC, Medical Research Council Dyspnoea
Score; SGRQ, St George’s respiratory questionnaire.
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were 0.054 (0.028 to 0.080) and 6.99 (3.78 to 10.20),
respectively.
There were signiﬁcant but weak-to-moderate correlations
between change in UI and EQ-VAS with change in disease-
speciﬁc HRQoL questionnaires (table 3). The slope, y-intercept
and correlation coefﬁcient between change in UI or EQ-VAS
with change in other outcome measures are shown in the online
supplementary material. The UI and VAS were not correlated
with the CATor SGRQ with a correlation coefﬁcient >0.3.
For change in UI, changes in CRQ-emotion, CRQ-mastery
and CRQ total were associated with a correlation coefﬁcient
>0.3—these were subsequently used as anchors to estimate the
Figure 2 Association between baseline EQ-5D-5L utility index (UI)
and visual analogue scale (VAS) with chronic respiratory disease
questionnaire (CRQ) total score. p Values all <0.001.
Figure 3 Mean (95% CIs) EQ-5D-5L utility index (UI) and visual analogue scale (VAS) stratiﬁed according to global initiative for chronic obstructive
lung disease (GOLD) spirometric stages, Medical Research Council (MRC) dyspnoea score and age dyspnoea obstruction (ADO) Index. p Values
derived from one-way analysis of variance.
Table 2 Baseline characteristics and response to pulmonary
rehabilitation (PR): n=324
Characteristic Baseline Change with PR
Age (years) 70.2 (69.2 to 71.2)
Male/female (n) 192/132
BMI (kg/m2) 28.3 (27.5 to 29.1)
FEV1 (% predicted) 49.8 (47.5 to 52.0)
MRC 3.3 (3.2 to 3.4) −0.67 (−0.77 to −0.58)
ISW (m) 240 (222 to 258) 48.5 (42.1 to 54.8)
5STS (s) 14.7 (14.0 to 15.3) −2.9 (−3.4 to −2.3)
4MGS (/ms) 0.88 (0.86 to 0.91) 0.13 (0.11 to 0.15)
SGRQ symptoms 66.1 (62.9 to 69.2) −4.0 (−6.6 to −1.4)
SGRQ activities 69.3 (66.3 to 72.2) −6.4 (−8.9 to −3.9)
SGRQ impact 35.8 (33.1 to 38.5) −4.9 (−6.8 to −3.0)
SGRQ total 50.8 (48.3 to 53.3) −5.1 (−6.8 to −3.4)
CRQ dyspnoea 14.2 (13.6 to 14.8) 4.5 (3.9 to 5.2)
CRQ fatigue 14.0 (13.4 to 14.6) 2.9 (2.5 to 3.4)
CRQ emotion 30.4 (29.4 to 31.4) 4.2 (3.4 to 5.1)
CRQ mastery 17.6 (17.0 to 18.2) 2.8 (2.3 to 3.3))
CRQ total 76.1 (73.7 to 78.4) 14.5 (12.5 to 16.5)
CAT 20.1 (18.9 to 21.3) −3.5 (−4.7 to −2.2)
Utility index 0.697 (0.673 to 0.720) 0.065 (0.047 to 0.083)
EQ-VAS 61.1 (58.9 to 63.3) 8.6 (6.5 to 10.7)
Data expressed as mean (95% CI).
4MGS, 4 m gait speed; 5STS, five repetition sit to stand; BMI, body mass index;
CAT, COPD assessment test; CRQ, chronic respiratory questionnaire; EQ-VAS, visual
analogue scale; ISW, incremental shuttle walk; MRC, Medical Research Council
Dyspnoea Score; SGRQ, St George’s respiratory questionnaire.
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MID for the UI. Using linear regression and the established
MID for each anchor, estimates of the MID for UI ranged from
0.059 and 0.062. Using the same anchors, ROC plots identiﬁed
estimates for the UI between 0.037 to 0.046 with C-statistic
ranging from 0.66 to 0.72 (see tables 4 and 5).
For change in EQ-VAS, changes in all CRQ domain and total
scores were associated with a correlation coefﬁcient >0.3 and
were subsequently used as anchors. For EQ-VAS, linear regres-
sion estimates of the MID ranged from 6.5 to 8.0 and ROC
consistently identiﬁed a cut-off of 6.5 with area under curve
(AUC) ranging from 0.65 and 0.69 (tables 4 and 5).
All estimates of the MID for UI and EQ-VAS are outlined in
table 5. Giving equal weighting to the anchor-derived estimates,
the mean (range) estimates for the MID for UI and EQ-VAS
were 0.051 (0.037–0.063) and 6.9 (6.5–8.0), respectively. If
prioritising the global rating of change questionnaire, which
measures patient assessment of improvement or decline directly,
similar mean estimates for the UI and EQ-VAS were observed
(0.054 and 6.99, respectively).
DISCUSSION
This study is the ﬁrst to demonstrate the validity of the
EQ-5D-5L UI and EQ-VAS in patients with COPD by showing
signiﬁcant correlations with established disease-speciﬁc HRQoL
questionnaires and an ability to differentiate between groups
deﬁned according to disease severity. Furthermore, we demon-
strate that the EQ-5D-5L is responsive to change following pul-
monary rehabilitation, and that change in EQ-5D-5L correlates
signiﬁcantly with change in disease-speciﬁc HRQoL measures.
Furthermore, to our knowledge, this is the ﬁrst study to pro-
spectively and purposely estimate the MID for both the
EQ-5D-5L directly calculated UI and EQ-VAS. Using anchors
measuring similar construct, we estimated the minimum import-
ant improvement in UI and VAS to be approximately 0.05 and
7.0, respectively.
The generic format of the EQ-5D enables comparisons of
health change to be made with other conditions. It has been
used in national surveys to measure population-level health
status, including the Health Survey for England, and is routinely
Figure 4 Distribution of responses to the descriptive system of the
EQ-5D-5L pre-pulmonary and post-pulmonary rehabilitation.
Figure 5 Mean (95% CIs) change (Δ) in EQ-5D-5L utility index (UI)
and visual analogue scale (VAS) according to response to global rating
of change questionnaire (GRCQ). 1=‘much better’; 2=‘a little better’;
3=‘the same’; 4=‘a little worse’; 5=‘much worse’. Responses 3–5 were
combined due to small numbers—>90% reported feeling ‘much better’
or ‘a little better’ following pulmonary rehabilitation.
Table 3 Correlation coefficients of change in EQ-5D-5L utility
index and EQ-VAS with pulmonary rehabilitation against external
anchors
Variable r p Value
Utility index
ΔSGRQ symptoms −0.05 0.538
ΔSGRQ activities −0.12 0.185
ΔSGRQ impact −0.13 0.155
ΔSGRQ total −0.14 0.127
ΔCRQ dyspnoea 0.25 <0.001
ΔCRQ fatigue 0.29 <0.001
ΔCRQ emotion 0.39 <0.001
ΔCRQ mastery 0.31 <0.001
ΔCRQ total 0.40 <0.001
ΔCAT −0.14 0.111
EQ-VAS
ΔSGRQ symptoms −0.15 0.084
ΔSGRQ activities −0.11 0.205
ΔSGRQ impact −-0.27 0.002
ΔSGRQ total −0.21 0.020
ΔCRQ dyspnoea 0.31 <0.001
ΔCRQ fatigue 0.32 <0.001
ΔCRQ emotion 0.30 <0.001
ΔCRQ mastery 0.30 <0.001
ΔCRQ total 0.38 <0.001
ΔCAT −0.28 0.001
CAT, COPD assessment test; CRQ, chronic respiratory questionnaire; SGRQ, St
George’s respiratory questionnaire; Δ, change.
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used as a measure of organisational performance in delivering
some common treatments in the UK.27 The breadth of dimen-
sions included in the instrument enables comorbidities and
adverse effects of treatment to be captured in a single measure.
Furthermore, the availability of a utility value set enables its use
in the cost-effectiveness analyses of treatments, which is
accepted or recommended by several health technology assess-
ment agencies.2 28 29
To our knowledge, this is the ﬁrst study to directly calculate
values for the UI, following the recent publication of the
EQ-5D-5L Value Set for England.14 Previous studies have only
estimated the UI by using a Crosswalk Index Value Calculator
that maps scores from the 5L to the 3L.11 An example in the
COPD literature is the study from Lin and colleagues.30
Convergent validation was against the PROMIS-43 short-form
questionnaire, which itself has not been well validated in
COPD.30
Our analysis of the psychometric properties of the UI, derived
from the Value Set for England, is likely to be of interest to
investigators using the EQ-5D-5L in both patients with COPD
and other populations. Our results were based on large sample
sizes (616 patients for the assessment of validity, 324 patients
for the assessment of responsiveness and MID). High response
rates were achieved, with a 99% questionnaire completion rate
in study 1 and 81% completion rate in the longitudinal study 2
(completion at both time points). We also used multiple well-
established, validated disease-speciﬁc HRQoL measures, includ-
ing the SGRQ, CRQ, CCQ and CAT. The ﬁndings for
EQ-5D-5L were robust to the choice of comparator measure,
providing some internal corroboration of our ﬁndings.
Previous studies relating to the psychometric properties of the
three-level version of the EQ-5D in COPD have had mixed con-
clusions. Pickard et al31 identiﬁed 12 relevant studies and con-
cluded that EQ-5D-3L was a reliable (test–retest) and valid
measure of health status in people with COPD; however, they
noted limited ability of EQ-5D-3L to differentiate between
milder stages of disease deﬁned using the GOLD criteria—a
similar ﬁnding for the EQ-5D-5L was observed in our study.
Although this may be construed as a weakness of the question-
naire, it is well recognised that the relationship between FEV1
and HRQoL is poor in COPD.32 Furthermore, in our study,
both UI and EQ-VAS were able to differentiate categories of
other validated measures of disease severity, including the MRC
Dyspnoea Scale and the composite ADO index (ﬁgure 3).
Petrillo et al33 demonstrated ceiling effects with 13% of all
patients reporting no problems in all dimensions at discharge
from hospital despite patients having severe or very severe
COPD. In a previous study of severe or very severe patients
with COPD undergoing pulmonary rehabilitation, Ringbaek
et al observed that 12.7% reported ‘perfect’ health at baseline,
increasing to 17.9% after rehabilitation. In contrast, despite our
study cohort having milder spirometric abnormality, we
observed a lower prevalence of ceiling effect. Also, 7% of study
1 and 6% (pre-rehabilitation) and 11% (post-rehabilitation)
reported perfect health following. This provides evidence that
the 5-level EQ-5D has a smaller ceiling effect than the three-
level questionnaire in patients with COPD.
The responsiveness of the EQ-5D-3L has been reported previ-
ously.6 34 35 Ringbaek et al6 demonstrated that the 3L UI
improved signiﬁcantly with rehabilitation, but was less respon-
sive than SGRQ or endurance shuttle walk time. The EQ-VAS
Table 5 Anchor-based and distribution-based estimates of the
minimum important difference (MID) of the EQ-5D-5L utility index
and EQ-VAS
Approach Anchor/method MID estimate
Utility index Distribution 0.5 SD 0.109
Mean change GRCQ 0.054
Linear regression CRQ emotion 0.063
Linear regression CRQ mastery 0.062
Linear regression CRQ total 0.059
ROC CRQ emotion 0.046
ROC CRQ mastery 0.038
ROC CRQ total 0.037
EQ-VAS Distribution 0.5 SD 10.1
Mean change GRCQ 6.9
Linear regression CRQ dyspnoea 6.5
Linear regression CRQ fatigue 7.2
Linear regression CRQ emotion 8.0
Linear regression CRQ mastery 7.6
Linear regression CRQ total 6.7
ROC CRQ dyspnoea 6.5
ROC CRQ fatigue 6.5
ROC CRQ emotion 6.5
ROC CRQ mastery 6.5
ROC CRQ total 6.5
CRQ, chronic respiratory questionnaire; GRCQ, global rating of change questionnaire;
ROC, receiver operating characteristic curves.
Table 4 Receiver operating characteristic curves to identify estimates of EQ-5D-5L that best identified achievement of the minimum important
difference of the anchor, giving equal weighting to sensitivity and specificity
Anchor Cut-point Sensitivity (%) Specificity (%) AUC p Value
Utility index
CRQ emotion 0.046 66.3 66.5 0.72 <0.001
CRQ mastery 0.038 63.5 63.7 0.66 <0.001
CRQ total 0.037 65.6 66.4 0.69 <0.001
EQ-VAS
CRQ dyspnoea 6.5 70.0 62.0 0.69 <0.001
CRQ fatigue 6.5 56.1 66.1 0.65 <0.001
CRQ emotion 6.5 61.5 68.0 0.68 <0.001
CRQ mastery 6.5 58.5 67.9 0.66 <0.001
CRQ total 6.5 59.1 69.8 0.67 <0.001
AUC, area under curve or C-statistic; CRQ, chronic respiratory questionnaire.
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showed no signiﬁcant improvement with rehabilitation. In con-
trast, our study showed larger changes in 5L UI and EQ-VAS
both in absolute terms and in terms of standardised response
means. This could be accounted for by differences in the inter-
vention or population, but could also reﬂect increased respon-
siveness of the EQ-5D-5L questionnaire. However, we still
found the responsiveness of the EQ-5D-5L to be lower than the
disease-speciﬁc HRQoL questionnaires or physical performance
measures.
Our study is the ﬁrst to report the MID of the EQ-5D-5L UI.
Walters and Brazier have previously reported estimates for the
three-level version of the EQ-5D from eight longitudinal studies
in 11 patient groups, including COPD.35 Based on a 0.5 SD
approach, they report estimates of MID of 0.12 and 0.15,
which are similar but slightly higher than our results for
EQ-5D-5L of 0.11. However, our anchor-based estimates of
MID differed substantially from those previously reported.
Mean changes in 3L UI for patients with COPD reporting their
health to be ‘somewhat better’ were widely divergent at 0.013
and −0.128 in the study by Walters and Brazier,35 although this
was based on a very small sample size (n=9), explaining the
wide CIs (including negative values) and lack of precision.35 In
comparison, the mean change in EQ-5D-5L UI in our study was
a more congruent 0.054 for patients reporting feeling ‘a little
better’ in our study.
Although the determination of the MID remains controversial
with no ﬁrm consensus on methodology,16 our study used both
distribution-based and anchor-based methods and provided 8
and 12 estimates of the MID for the UI and EQ-VAS, respect-
ively (table 3). The anchor-based estimates were broadly consist-
ent, although it was noted that the relationship between change
in EQ-5D-5L and change in anchor questionnaires was only
modest. The MID of the 5L EQ-VAS has only previously been
estimated in a retrospective study that evaluated the response of
the EQ-VAS to a 3-week inpatient rehabilitation programme. In
contrast to our study, the authors only used a single anchor
(a breathlessness score, rather than a HRQoL questionnaire).36
Using an ROC plot, the cut-off identiﬁed was 8, which is higher
than the estimates generated in our study. This may reﬂect dif-
ferences in the cohort populations, intervention and choice of
anchor.
There were some limitations to this study. We did not explore
test–retest reliability of the EQ-5D-5L, although this has been
conﬁrmed in non-COPD populations.37–39 The patients were
recruited from secondary care or pulmonary rehabilitation
clinics populated with symptomatic outpatients and so whether
similar ﬁndings would be obtained in patients with milder (eg,
in those managed exclusively in primary care setting) or more
severe disease (eg, acutely hospitalised inpatients) is open to
further study. In addition, participants completed the question-
naires in the clinic setting where health professionals were on
hand to answer questions. It is possible that the extremely high
response rates obtained here may not be replicated in studies
using other modes of administration, for example, by post or
online. Another limitation of the study is the lack of a gold
standard measure of HRQoL with which to compare. However,
we employed a range of measures of HRQoL and clinical
indices in this study, all of which have been previously validated
in patients with COPD. The overall results were robust to the
choice of measure used, although the strongest relationships
were observed for the ‘total’ scores of the COPD-speciﬁc mea-
sures that capture a variety of impacts on functioning and symp-
toms. Furthermore, although the EQ-5D-5L was validated
against a variety of measures, the predictive ability of this
questionnaire was not explored. Future longitudinal studies
would be of interest as there is a paucity of information on this
topic.
In summary, our ﬁndings demonstrate that the EQ-5D-5L is a
valid and responsive measure of HRQoL in people with COPD.
Although some ceiling effects and lack of responsiveness persist
with the EQ-5D-5L, these appear to be reduced compared with
results previously reported for the EQ-5D-3L.10 Given the
importance of the EQ-5D-5L in health economic analyses,
inclusion in clinical studies of COPD would provide useful add-
itional cost-effectiveness data of interest to health technology
agencies.
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